Chronic Prostatitis / Chronic Pelvic Pain Syndrome

Chronic prostatitis is common — an estimated 8% global incidence, and up to 25% of urology outpatient visits — but genuine bacterial infection is rare. The NIH classifies it into four categories:

Category	Name	Notes
I	Acute bacterial prostatitis	See Acute Prostatitis
II	Chronic bacterial prostatitis	<10% of chronic prostatitis; positive culture
III	Chronic pelvic pain syndrome (CPPS)	~90% of cases; no organism identified
IV	Asymptomatic inflammatory prostatitis	Incidental histological finding; no treatment needed

Chronic bacterial prostatitis (Category II)

True chronic bacterial prostatitis is rare — fewer than 10% of men presenting with chronic prostatitis symptoms have a confirmed bacterial infection.

Clinical features: recurrent UTIs with culture of a recognised uropathogen; typically intermittent episodes resembling acute prostatitis but without fever.

Investigations: the 2-glass test (pre- and post-prostate-massage urine, compared) is the practical option — a rise in leukocytes/bacterial count post-massage supports a prostatic source. The 4-glass (Meares–Stamey) test is the historical gold standard but is cumbersome and rarely used in practice.

Treatment: an extended course of antibiotics — ciprofloxacin 500mg BD, norfloxacin 400mg BD, or trimethoprim 300mg nocte — for 4 weeks; up to 12 weeks gives the highest cure rates and may be needed for relapse. Persistent prostatic calculi can act as a nidus for relapse.

Chronic pelvic pain syndrome (Category III)

The much more common diagnosis when chronic prostatitis symptoms occur without a positive culture — accounts for roughly 90% of chronic prostatitis presentations, and is the most frequent urological diagnosis in men under 50. Presents as chronic pelvic/perineal/genital pain (≥ 3 of the past 6 months) with variable urinary symptoms, made after excluding chronic bacterial prostatitis, bladder outlet obstruction, and prostate cancer.

The UPOINT(S) classification (urinary, psychosocial, organ-specific, infection, neurological/systemic, tenderness, sexual dysfunction) helps phenotype patients and target therapy, since no single treatment works for everyone.

Management (evidence is modest for any single therapy; a multimodal approach is standard):

• Alpha-blockers (e.g. tamsulosin) — particularly if voiding symptoms are prominent.
• NSAIDs/analgesia for symptomatic pain control.
• Pelvic floor physiotherapy — trigger-point release and myofascial work, most helpful when pelvic floor spasm/tenderness is prominent.
• A short (2–4 week) trial of antibiotics is reasonable in newly diagnosed, previously-untreated patients even with a negative culture, but antibiotics are not indicated once chronic bacterial prostatitis has been excluded and an initial trial hasn’t helped — prolonged empirical courses are not supported.
• Consider referral to urology if symptoms are refractory to first-line measures.